BCD-100
Проводит ЗАО «Биокад»
Страница компанииAn International Multicenter Open-label Randomized Trial of the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) as Monotherapy in Patients With Unresectable/Metastatic Melanoma.
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT03269565/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Статус исследования в реестре не указан — уточняйте в центре.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 126 чел. во всех странах исследования.
- Центров в реестре: 9 в 3 городах. Список — ниже на странице.
- Плановая дата окончания (01.2021) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Состояние пациента (ECOG)0–1
- Биомаркеры в критерияхPD-L1
- Стадияметастатическая (IV)
- Метастазы в головной мозгактивные — не включают
- Ожидаемая продолжительность жизнине меньше 12 нед.
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 12 · невключение: 36
Критерии включения
- Signed Informed Consent Form and the subject's ability to follow the Protocol requirements;
- Age: 18 years and older at the signing of the informed consent;
- Histologically verified (documented) unresectable/metastatic melanoma;
- Newly diagnosed advanced/metastatic melanoma or progressive disease during (or after) systemic chemotherapy ;
- Available tissue blocks for histological examination or patient's agreement to give biopsy specimens for PD-L1 expression status ;
- ECOG performance status of 0 or 1;
- LDH less than or equal to 2×upper limit of normal;
- At least one RESICT 1.1-defined measurable target lesion confirmed by an independent review;
- All prior treatment-related toxicities/surgery-related adverse events must be less than or equal to Grade 2 according to CTCAE 4.03, except for chronic/permanent damage caused by an AE that does not affect the safety profile of the investigational therapy (e.g., alopecia);
- Adequate organ system function ;
- Life expectancy of at least 12 weeks from the screening.
- Patients with reproductive potential must agree to practice acceptable methods of birth control throughout the entire trial period, starting from signing the informed consent and up to 12 weeks after the last dose of BCD-100.
Критерии невключения
- Evidence of severe or concomitant diseases/life-threatening complications of the main condition (e.g., massive pleural, pericardial, or peritoneal effusion that requires medical intervention , pulmonary lymphangitis) at the signing of the informed consent;
- Subjects with progressive/symptomatic brain metastases (e.g., brain edema, spinal cord compression) or brain metastases that need therapy with corticosteroids and/or anticonvulsants ;
- Any concomitant disease observed at the screening that increases the risk of adverse events during the investigational therapy:
- Grade III-IV stable angina, unstable angina, or a history of myocardial infarction within 6 months prior to signing the informed consent;
- Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system;
- Severe, resistant hypertension;
- History of atopic asthma, angioedema;
- Moderate to severe respiratory failure, Grade 3 to 4 chronic obstructive pulmonary disease;
- Any other concomitant condition (e.g., metabolism, blood, hepatic, renal, pulmonary, neurological, endocrine, cardiac, infectious, or gastrointestinal disorder) that constitutes an unacceptable risk to the patient's health during the investigational therapy;
- Systemic autoimmune diseases (including but not limited to SLE, Crohn's disease, ulcerative colitis, systemic scleroderma, inflammatory myopathy, mixed connective tissue disease, overlap syndrome, etc.) ;
- Endocrine disorders that cannot be adequately controlled by hormone replacement therapy without any dose modification within 28 days prior to the start of the investigational therapy;
- Patients who need therapy with corticosteroids or other immunosuppressants;
- Blood disorders :
- Neutrophils <1.5×109/L;
- Platelets <100×109/L;
- Hb <90 g/L;
- Impaired renal function: creatinine ≥1.5×ULN;
- Impaired liver function :
- Bilirubin ≥1.5×ULN (≤50 μmol/L for patients with Gilbert's syndrome);
- AST/ALT ≥2.5×ULN (5×ULN for patients with liver metastases);
- ALP ≥5×ULN;
- LDH >2×ULN;
- Anti-cancer therapy (surgery, chemotherapy) within 28 days prior to the first dose of the investigational product; radiotherapy within 14 days prior to the first dose of the investigational product;
- Prior treatment with anti-CTLA4 and/or anti-PD-1/PD-L1/PD-L2 agents;
- Prior targeted therapy ;
- Patients who have received more than two lines of systemic chemotherapy for unresectable or metastatic melanoma;
- Concomitant cancer (except for cervical carcinoma in situ after radical surgery or basal cell/squamous cell carcinoma after radical surgery);
- Any condition that prevents a patient from following the Protocol procedures (dementia, neurological or mental disorders, drug/alcohol abuse, etc.) ;
- Simultaneous participation in other clinical trials , participation in other clinical trials within 30 days prior to the first dose of the investigational product;
- Acute infection or the acute phase of chronic infection within 28 days prior the first dose of the investigational product;
- Active HBV/HCV/HIV infection, active syphilis ;
- Patients unable to receive an IV infusion of BCD-100;
- Patients unable to receive an IV contrast agent;
- Hypersensitivity to any of the components of BCD-100;
- History of hypersensitivity to any therapeutic monoclonal antibody;
- Pregnant or lactating female.
Источник: ClinicalTrials.gov, NCT03269565 · запись обновлена в реестре 18 сентября 2020.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 2
- Overall response rate — 1 year
Цель исследования
An International Multicenter Open-label Randomized Trial of the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) as Monotherapy in Patients with Unresectable/Metastatic Melanoma.
Где проходит
9 центров в 3 городах- Saint Petersburg Clinical Research and Practice Center for Specialized Medical Care (Oncology)
- Federal State Budgetary Institution «N.N. Petrov Research Institute of Oncology» of the Ministry of Healthcare of the Russian Federation (FSBI N.N. Petrov RIO (Chemotherapy Department with Innovative Technologies)
- Federal State Budgetary Institution «N.N. Petrov Research Institute of Oncology» of the Ministry of Healthcare of the Russian Federation, Research Department of the Innovative Methods of Therapeutic Oncology and Rehabilitation (FSBI N.N. Petrov RIO of the
- State Budgetary Institution of Healthcare «Clinical Oncology Dispensary of Chelyabinsk Region» (SBIH CODCR)
- ООО «БиоЭк»
- ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Минздрава России
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03269565 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.